Meiji Yasuda Asset Management Co Ltd. Buys 16,184 Shares of Boston Scientific Co. (NYSE:BSX)

Meiji Yasuda Asset Management Co Ltd. lifted its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 20.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 96,555 shares of the medical equipment provider's stock after buying an additional 16,184 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.'s holdings in Boston Scientific were worth $8,624,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Mechanics Bank Trust Department bought a new position in shares of Boston Scientific in the fourth quarter worth about $415,000. Highland Capital Management LLC bought a new position in Boston Scientific in the 4th quarter worth approximately $4,887,000. Covenant Asset Management LLC acquired a new position in Boston Scientific during the 4th quarter worth $3,405,000. Brookstone Capital Management boosted its position in Boston Scientific by 23.7% in the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock valued at $9,455,000 after buying an additional 20,307 shares during the last quarter. Finally, Beacon Investment Advisory Services Inc. increased its stake in shares of Boston Scientific by 31.7% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock valued at $1,744,000 after buying an additional 4,702 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the sale, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 137,302 shares of company stock valued at $14,319,269. 0.50% of the stock is owned by insiders.

Remove Ads

Boston Scientific Stock Down 1.5 %

BSX traded down $1.51 during trading on Friday, reaching $99.29. The company had a trading volume of 7,402,670 shares, compared to its average volume of 6,051,507. The business's fifty day moving average price is $102.16 and its 200 day moving average price is $93.11. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 12 month low of $66.80 and a 12 month high of $107.17. The company has a market cap of $146.86 billion, a P/E ratio of 79.43, a PEG ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BSX. Barclays upped their price target on Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a research report on Monday, March 3rd. Canaccord Genuity Group lifted their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. StockNews.com lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 8th. Finally, Raymond James raised their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific presently has an average rating of "Moderate Buy" and an average target price of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.